Delpharm and Famar, European leaders in contract manufacturing and development of medicines for pharmaceutical laboratories, have entered into exclusive negotiations for the acquisition by Delpharm of 5 Famar manufacturing sites in France, the Netherlands and Canada.
 
The transaction involves the takeover of the French sites located in Orléans (Loiret), Aigle (Orne) and St-Rémy-sur-Avre (Eure-et-Loire), the Pointe-Claire site in Quebec, and that of Bladel in the Netherlands. The group of 5 sites represents a turnover of €250 million and more than 1,300 employees.
 
The binding offer submitted by Delpharm to Famar remains subject, amongst other, to the approval of the competition authority. The transaction is expected to be completed by early November 2019.
 
“The acquisition of the 5 Famar sites constitutes an important step towards our goal to become the drug manufacturer of choice for our major French and foreign clients,” said Sébastien Aguettant, president, Delpharm. “We ambitiously welcome the teams of these 5 sites and we are happy that they will join the 3,300 employees in the 12 existing sites of Delpharm.”
 
Patrick Puy, president, Famar, said, “The board of directors has agreed that the offer proposed by Delpharm is in the best interest of the 5 sites and their employees. The completion of this transaction will allow these sites to enter into a new phase of sustainable and promising development.”